Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
| Autor: | Li Tong, Baolan Li, Peter Lin, Yanxia Liu, Yuan Gao, Fanbin Hu, Ying Wang, Tongmei Zhang, Lina Zhang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Aneuploidy Vimentin 03 medical and health sciences 0302 clinical medicine Circulating tumor cell Internal medicine Medicine Humans Progression-free survival Prospective Studies Lung cancer Advanced lung cancer Chemotherapy Hematology biology business.industry Hazard ratio Liver Neoplasms Circulating tumor cells Aneuploidy of Chr8 General Medicine Middle Aged medicine.disease Neoplastic Cells Circulating Cell size 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Female business Original Article – Cancer Research Chromosomes Human Pair 8 Follow-Up Studies |
| Zdroj: | Journal of Cancer Research and Clinical Oncology |
| ISSN: | 1432-1335 |
| Popis: | Objective To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. Methods Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy. Results Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim+ CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim+ CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim+ CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim+ CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim+ CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239–6.131; p = 0.013]. Conclusions This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim+ CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim+ CTCs is correlated with liver metastases and may help predict poor PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink